Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates if temsirolimus causes a reduction in the serum levels of
prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer
(CRPC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sandy Srinivas
Collaborators:
American Society of Clinical Oncology National Comprehensive Cancer Network Wyeth is now a wholly owned subsidiary of Pfizer